The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53
Abstract
The central role of the p53 tumor suppressor gene product in oncogenesis is gradually being clarified. Point mutations in the p53 tumor suppressor gene are common in most human cancers and are often associated with p53 protein overexpression. Overexpressed wild‐type or mutant determinants of the p53 protein thus represent an attractive target for immunotherapy of cancer directed against a structure involved in malignant transformation. An important step towards this goal is identification of epitopes of p53 that can be recognized by human cytotoxic T lymphocytes. We identified peptides of (mutant) p53 capable of binding to HLA‐A2.1 in an in vitro assay. These HLA‐A2.1‐binding peptides were utilized for in vitro induction of primary cytotoxic T lymphocyte responses using a human processing‐defective cell line (174CEM.T2) as antigen‐presenting cell. These cells display “empty” HLA class I surface molecules, that can efficiently be loaded with a single peptide. We obtained CD8+ cytotoxic T lymphocyte clones capable of specifically lysing target cells loaded with wild‐type or tumor‐specific mutant p53 peptides. This strategy allows the in vitro initiation of human cytotoxic T lymphocyte responses against target molecules of choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
Antigen Recognition by Class I-Restricted T Lymphocytes
Townsend, A., & Bodmer, H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.003125 · Cited by 1,198
Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry
Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546328 · Cited by 1,198
Association of class I major histocompatibility heavy and light chains induced by viral peptides
Townsend, A., Öhlén, C., Bastin, J., Ljunggren, H.-G., Foster, L., & Kärre, K. (1989) · Nature · doi:10.1038/340443a0 · Cited by 985
Empty MHC class I molecules come out in the cold
Ljunggren, H.-G., Stam, N. J., Öhlén, C., Neefjes, J. J., Höglund, P., Heemels, M.-T., Bastin, J., Schumacher, T. N. M., Townsend, A., Kärre, K., et al. (1990) · Nature · doi:10.1038/346476a0 · Cited by 926
Cited by
Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethé, B., Brasseur, F., & Boon, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.921 · Cited by 762
Structure, chromosomal localization, and expression of 12 genes of the MAGE family
De Plaen, E., Traversari, C., Gaforio, J. J., Szikora, J.-P., De Smet, C., Brasseur, F., van der Bruggen, P., Lethé, B., Lurquin, C., Chomez, P., et al. (1994) · Immunogenetics · doi:10.1007/bf01246677 · Cited by 586
Fisk, B., Blevins, T. L., Wharton, J. T., & Ioannides, C. G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.6.2109 · Cited by 543
Alexander-Miller, M. A., Leggatt, G. R., & Berzofsky, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4102 · Cited by 501
Coulie, P. G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423
van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boël, P., De Smet, C., Traversari, C., Townsend, A., & Boon, T. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241218 · Cited by 367
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998) · Blood · doi:10.1182/blood.v92.5.1471 · Cited by 323
Celis, E., Tsai, V, Crimi, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., & Serra, H. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2105 · Cited by 306
Brossart, P., Heinrich, K. S., Stuhler, G., Behnke, L., Reichardt, V. L., Stevanovic, S., Muhm, A., Rammensee, H.-G., Kanz, L., & Brugger, W. (1999) · Blood · doi:10.1182/blood.v93.12.4309 · Cited by 306
Targeting p53 as a general tumor antigen.
Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., & Sherman, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.11993 · Cited by 304
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
Harris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 285
Correale, P., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., Tsang, K. Y., & Konstantin, W. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.4.293 · Cited by 264
Karanikas, V, Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V, Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119825 · Cited by 263
Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
Theobald, M., Biggs, J., Hernández, J., Lustgarten, J., Labadie, C., & Sherman, L. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.5.833 · Cited by 256
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., & DeLeo, A. B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1357 · Cited by 253
Speetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185
Self-citation
Metadata
- Authors
- Houbiers, J. G. A., Nijman, H. W., Van Der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van De Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., & Melief, C. J. M.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1993-09
- Volume
- 23
- Issue
- 9
- Pages
- 2072-2077
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2123524669
- Cited by
- 258
- References
- 40
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.